Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim
Management of severe psoriasis in a renal transplant recipient with latent tuberculosis using risankizumab. (PubMed, J Dtsch Dermatol Ges) - Sep 18, 2026 - No abstract available 
Journal • Dermatology • Immunology • Infectious Disease • Psoriasis • Pulmonary Disease • Respiratory Diseases • Transplantation • Tuberculosis
http://www.ncbi.nlm.nih.gov/pubmed/42750393
 
Aadarsh Shah; Anthony Bewley; April Lauren R Goundry; Magdi Yaqoob; Malvina Cunningham; Maria-Angeliki Gkini
 
Sep 18, 2026
 
Prev Next